Aurora Interactive and Galderma to Develop the World Leading Digital Dermatology Research Tool

| March 17, 2011

MONTREAL, CANADA–Aurora Interactive, a world leader in digital pathology communications, announced Thursday the company has signed a partnership contract with Galderma, a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology.

The partnership contract is aimed at developing its mScope communication platform and viewer for dermatology research & development at Galderma's R&D center at Sophia Antipolis, France. Galderma forms licensing partnerships around innovative product candidates and technologies.

"The partnership between Aurora and Galderma will allow the adaptation of the best digital technology suite to achieve both companies ambitious goals," said Pierre Le Fèvre, president and chief executive officer for Aurora Interactive. "We are extremely proud to be associated with furthering dermatology research. The decision to facilitate collaboration between researchers is consistent with our company's collaborative Web 2.0 philosophy and mScope product" he added.

The 19,300-sq. meter state-of-the-art R&D center at Sophia Antipolis is Galderma's largest facility and positions the company as the world's leading investor in dermatology R&D. To drive sustained growth, Galderma invests approximately 20 percent of its revenues to discover and develop new drugs and access innovative technologies

About Aurora Interactive Ltd.

Aurora Interactive has developedthe leadingweb-based software platform (mScope) for simplification, productivity, and ease of communications.mScope's Universal Web Viewer has collaborative tools to view medical slides and images anytime, anywhere, regardless of file format.The software has three applications to aid digital pathology web-based communications: mScope Education, mScope Clinical, and mScope Universal Viewer. Aurora's mission is to improve patient outcomes and help members of the medical community achieve their full potential by eliminating the learning, diagnostic, and collaborative restrictions imposed by time and space.

About Galderma

Founded in 1981, Galderma is a joint venture between Nestlé and L'Oréal and today employs more than 3,000 people. The company, headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. In 2009, sales reached 978 million Euros, an increase of 10.8%* over 2008. Committed to the future of dermatology, Galderma's ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians.

Category: Digital Pathology News, Pathology News

Comments (1)

Trackback URL | Comments RSS Feed

  1. “Unnecessary risks are being taken by patients seeking the liberation treatment.” says Dr. Avneesh Gupte of the CCSVI Clinic. “It has been our contention since we started doing minimally invasive venous angioplasties nearly 6 years ago that discharging patients who have had neck vein surgery on an outpatient basis is contra-indicated. We have been keeping patients hospitalized for a week to 10 days as a matter of safety and monitoring them for symptoms. Nobody who has the liberation therapy gets discharged earlier than that. During that time we do daily Doppler Ultrasounds, blood work and blood pressure monitoring among other testing. This has been the safe practice standard that we have adopted and this post-procedure monitoring over 10 days is the subject of our recent study as it relates to CCSVI for MS patients.”
    Although the venous angioplasty therapy on neck veins has been done for MS patients at CCSVI Clinic only for the last 18 months it has been performed on narrow or occluded neck veins for other reasons for many years. “Where we encounter blocked neck veins resulting in a reflux of blood to the brain, we treat it as a disease,” says Gupte. “It’s not normal pathology and we have seen improved health outcomes for patients where we have relieved the condition with minimal occurrences of re-stenosis long-term. We believe that our record of safety and success is due to our post-procedure protocol because we have had to take patients back to the OR to re-treat them in that 10-day period. Otherwise some people could have run into trouble, no question.”
    Calgary MS patient Maralyn Clarke died recently after being treated for CCSVI at Synergy Health Concepts of Newport Beach, California on an outpatient basis. Synergy Health Concepts discharges patients as a rule without in-clinic provisions for follow up and aftercare. Post-procedure, Mrs. Clarke was discharged, checked into a hotel, and suffered a massive bleed in the brain only hours after the procedure. Dr. Joseph Hewett of Synergy Health recently made a cross-Canada tour promoting his clinic for safe, effective treatment of CCSVI for MS patients at public forums in major Canadian cities including Calgary.
    “That just couldn’t happen here, but the sooner we develop written standards and best practices for the liberation procedure and observe them in practice, the safer the MS community will be”, says Dr. Gupte. “The way it is now is just madness. Everyone seems to be taking shortcuts. We know that it is expensive to keep patients in a clinical setting over a single night much less 10 days, but it’s quite absurd to release them the same day they have the procedure. We have always believed it to be unsafe and now it has proven to be unsafe. The thing is, are Synergy Health Concepts and other clinics doing the Liberation Treatment going to be changing their aftercare methods even though they know it is unsafe to release a patient on the same day? The answer is no, even after Mrs. Clarke’s unfortunate and unnecessary death. Therefore, they are not focused on patient safety…it’s become about money only and lives are being put at risk as a result.”
    Joanne Warkentin of Morden Manitoba, an MS patient who recently had both the liberation therapy and stem cell therapy at CCSVI Clinic agrees with Dr. Gupte. “Discharging patients on the same day as the procedure is ridiculous. I was in the hospital being monitored for 12 days before we flew back. People looking for a place to have the therapy must do their homework to find better options. We found CCSVI Clinic and there’s no place on earth that’s better to go for Liberation Therapy at the moment. I have given my complete medical file from CCSVI Clinic over to my Canadian physician for review.” For more information Log on to OR Call on Toll Free: 888-419-6855.